Dosing / Administration
Revolade dosing requirements must be individualised based on the patient's platelet counts. The lowest dose of eltrombopag to achieve and maintain a platelet count ≥50,000/µl should be used,...
Revolade dosing requirements must be individualised based on the patient's platelet counts. The lowest dose of eltrombopag to achieve and maintain a platelet count ≥50,000/µl should be used,...
The clinical efficacy and safety of asciminib in the treatment of patients with Philadelphia chromosome‑positive myeloid leukaemia in chronic phase (Ph+ CML‑CP) with treatment failure or intolerance to two or more tyrosine kinase inhibitors were...
Below is a selection of the observed side effects. Please refer to the SmPc for the complete list.
The most common adverse reactions of any grade (incidence ≥20%) in patients receiving asciminib were musculoskeletal pain (37.1%), upper...For which patients is Gilenya ® used?
GILENYA ® (fingolimod) is indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of...
Kisqali ® is reimbursed in Belgium, you can find the reimbursement conditions on the INAMI website .
E-HealthYou can request reimbursement by...